Drug targeting with nano-sized carrier systems

被引：170

作者：

Yokoyama M. ^{[1
]}

机构：

[1] Kanagawa Academy of Science and Technology, KSP East 404, Kawasaki, Kanagawa 213-0012

来源：

Journal of Artificial Organs | 2005年 / 8卷 / 2期

关键词：

Drug carrier; Drug targeting; EPR effect; Nano; Targeting;

D O I：

10.1007/s10047-005-0285-0

中图分类号：

学科分类号：

摘要：

This paper discusses the present status of, and future perspectives on, drug targeting through the bloodstream by describing the drug targeting concept, its methodologies, types of drug carriers, and recent clinical examples. This explanation and discussion is made from the viewpoint of possible correlations with studies on artificial organs, implants, and biomaterials. Two targeting methodologies (active and passive targeting), two targeting strategies (the magic bullet and the enhanced permeability and retention effect), and five types of drug carriers are explained. In addition, the clinical status of the five carrier systems is discussed. © The Japanese Society for Artificial Organs 2005.

引用

页码：77 / 84

页数：7

共 47 条

[1]

Yokoyama M., Okano T., Targetable drug carriers: Present status and a future perspective, Adv Drug Deliv Rev, 21, pp. 77-80, (1996)

[2]

Sugiyama Y., Importance of pharmacokinetic considerations in the development of drug delivery systems, Adv Drug Deliv Rev, 19, pp. 333-334, (1996)

[3]

Takakura Y., Maruyama K., Yokoyama M., Passive targeting of drugs (in Japanese), Drug Deliv Syst, 14, pp. 425-426, (1999)

[4]

Matsumura Y., Maeda H., A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs, Cancer Res, 46, pp. 6387-6392, (1986)

[5]

Maeda H., The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting, Adv Enzyme Regul, 41, pp. 189-207, (2001)

[6]

Litzinger D.C., Buiting A.M.J., Van Rooijen N., Huang L., Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes, Biochim Biophys Acta, 1190, pp. 99-107, (1994)

[7]

Seymour L.W., Miyamoto Y., Maeda H., Brereton M., Strohalm J., Ulbrich K., Duncan R., Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug, Eur J Cancer, 31, pp. 766-770, (1995)

[8]

Hamann P.R., Berger M.S., Page M., Mylotarg: The first antibody-targeted chemotherapy agent, Tumor Targeting in Cancer Therapy, pp. 239-254, (2002)

[9]

Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellstrom K.E., Cure of xenografted human carcinomas by BR-96-doxorubicin immunoconjugates, Science, 261, pp. 212-215, (1993)

[10]

Putnam D., Kopecek J., Polymer conjugates with anticancer activity, Adv Polymer Sci, 122, pp. 55-123, (1995)

← 1 2 3 4 5 →